IBIO, INC. Accumulated Other Comprehensive Income
IBIO, INC. (IBIO) had Accumulated Other Comprehensive Income of -$45.00 thousand as of 2026-06-30, per its 10-K filed 2026-08-28.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-28
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$45.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$21.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $10.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$15.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$45.00K 10-K · filed 2026-08-28 |
| 2026-03-31 | -$21.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $10.00K 10-Q · filed 2026-02-10 |
| 2025-09-30 | -$15.00K 10-Q/A · filed 2025-11-17 |
| 2022-12-31 | -$167.00K 10-Q/A · filed 2023-05-19 |
| 2022-09-30 | -$223.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$213.00K 10-K · filed 2023-09-27 |
| 2022-03-31 | -$194.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$91.00K 10-Q · filed 2022-02-14 |
| 2021-09-30 | -$64.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$63.00K 10-K · filed 2022-10-11 |
| 2021-03-31 | -$70.00K 10-Q · filed 2021-05-17 |
| 2020-12-31 | -$53.00K 10-Q · filed 2021-02-16 |
| 2020-09-30 | -$40.00K 10-Q · filed 2020-11-16 |
| 2020-06-30 | -$33.00K 10-K · filed 2021-09-28 |
| 2020-03-31 | -$33.00K 10-Q · filed 2020-05-15 |
| 2019-12-31 | -$31.00K 10-Q · filed 2020-02-14 |
| 2019-09-30 | -$32.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | -$31.00K 10-K · filed 2020-10-13 |
| 2019-03-31 | -$31.00K 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$30.00K 10-Q · filed 2019-02-13 |
| 2018-09-30 | -$31.00K 10-Q · filed 2018-11-13 |
| 2018-06-30 | -$30.00K 10-K · filed 2019-08-26 |
| 2018-03-31 | -$29.00K 10-Q · filed 2018-05-11 |
| 2017-12-31 | -$29.00K 10-Q · filed 2018-02-14 |
| 2017-09-30 | -$29.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | -$29.00K 10-K · filed 2018-09-18 |
| 2017-03-31 | -$29.00K 10-Q · filed 2017-05-15 |
| 2016-12-31 | -$29.00K 10-Q · filed 2017-02-21 |
| 2016-09-30 | -$29.00K 10-Q · filed 2016-11-18 |
| 2016-06-30 | -$29.00K 10-K · filed 2017-09-15 |
| 2016-03-31 | -$31.00K 10-Q · filed 2016-05-23 |
| 2015-12-31 | -$33.00K 10-Q · filed 2016-02-22 |
| 2015-09-30 | -$34.00K 10-Q · filed 2015-11-13 |
| 2015-06-30 | -$25.00K 10-K · filed 2016-10-13 |
| 2015-03-31 | -$26.00K 10-Q · filed 2015-05-15 |
| 2014-12-31 | -$14.00K 10-Q · filed 2015-02-24 |
| 2014-09-30 | -$3.00K 10-Q · filed 2014-11-14 |
| 2014-06-30 | $0.00 10-K · filed 2015-10-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |